[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-breast-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-breast-cancer":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100627701","large-language-model-based-emotional-management-for-breast-cancer-patients-100627701",false,"NCT07452055","Large Language Model-Based Emotional Management for Breast Cancer Patients","Large Language Model-Based Emotional Management for Breast Cancer Patients: A Multi-center, Randomized, Controlled Trial","EMBRACE","Inclusion Criteria:\n\n* Provision of written informed consent;\n* Aged 18 years or over;\n* Histopathologically confirmed primary breast cancer;\n* Ownership of a smartphone and ability to independently operate the intervention system;\n* Regular use (at least three times per week) of one or more third-party social media platforms (e.g., Weibo, Douyin, or Xiaohongshu);\n* Clear consciousness, basic reading and writing ability (equivalent to primary education or above), and adequate communication capacity;\n* An estimated life expectancy of six months or longer, as assessed by the treating physician.\n\nExclusion Criteria:\n\n* Diagnosed with cognitive impairment or psychiatric disorders that substantially interfere with assessment or participation;\n* Pregnancy or lactation;\n* Presence of other malignant tumours, except for cured basal cell carcinoma of the skin or carcinoma in situ of the cervix, or severe organic disease (including cardiac, hepatic, or renal insufficiency);\n* Substance abuse (including alcohol or drug dependence) or current suicidal ideation;\n* Concurrent participation in other clinical trials or interventional studies that may interfere with outcome evaluation.","ALL","18 Years",{"count":20,"type":21},440,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study (study type: randomized controlled trial) aims to evaluate whether a large language model-based precision emotional management intervention can improve health-related quality of life among patients with primary breast cancer. The study will enroll adult women (≥18 years old) with pathologically confirmed primary breast cancer who own a smartphone, regularly use social media platforms, and have an expected survival of at least 6 months.\n\nThe primary questions this study seeks to answer are:\n\n1. Does the intervention improve health-related quality of life (EORTC QLQ-C30 summary score) at 6 months post-intervention?\n2. Does the intervention reduce anxiety, depression, cancer-related symptom burden, and unplanned hospitalizations in this population? With a control group in place, researchers will compare changes in health-related quality of life, anxiety, depression, and cancer-related symptom burden between the intervention group (receiving digital precision emotional management plus usual care) and the control group (receiving usual care only) to determine whether the intervention leads to significant improvements in these outcomes.\n\nParticipants will be required to:\n\n1. Complete baseline and follow-up assessments of health-related quality of life, anxiety, depression, and cancer-related symptoms at 1, 3, and 6 months post-randomization.\n2. For those in the intervention group, use the digital precision emotional management system autonomously for 6 months, including submitting self-reported emotional diaries and completing biweekly skill translation assessments.\n3. For all participants, report any adverse events and unplanned hospitalizations during the study period.",[27],"Primary Breast Cancer",[29,30,31],"Large language model","Emotional management","Health-related quality of life","NOT_YET_RECRUITING","2026-03-10",{"date":35,"type":36},"2026-03-12","ACTUAL",{"date":33,"type":21},{"date":39,"type":21},"2026-11-01",{"name":41,"class":42},"Nanfang Hospital, Southern Medical University","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":68},"100196980","breast-cancer-proteomics-and-molecular-heterogeneity-100196980","NCT01840293","Breast Cancer Proteomics and Molecular Heterogeneity","Inclusion Criteria:\n\n1. Patients diagnosed with primary breast cancer attending hospital for the resection of their tumour tissue\n\n   Or\n\n   -Patients with suspected or confirmed recurrent or metastatic breast cancer (Patient has a history of a biopsy- or surgically- (i.e. pathologically) confirmed primary breast cancer) attending hospital for the resection\u002Fbiopsy and\u002For treatment of tumour tissue\n\n   Or\n\n   -Patient with suspected (but not necessarily biopsy confirmed) newly diagnosed stage 4 breast cancer attending hospital for the resection\u002Fbiopsy and\u002For treatment of their tumour tissue\n2. Patients receiving neoadjuvant treatment are also eligible (if applicable)\n3. Patients have to be ≥ 18 years of age\n4. Patients must be able to give informed consent","FEMALE",{"count":52,"type":21},1780,"OBSERVATIONAL","Primary objective:\n\nThe primary objective is to define the proteomic and molecular characteristics of primary and recurrent\u002F metastatic breast tumours with special focus on the expression of S100 protein and the estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2) genes\n\nSecondary objective:\n\n* To expand our understanding of the complex molecular pathways dictating the progression of breast cancer and their response to different treatment regimes.\n* To relate proteomic findings to survival data\n* To identify potential serum markers of breast cancer progression",[27,56],"Recurrent\u002FMetastatic Breast Cancer","RECRUITING","2025-12-15",{"date":60,"type":36},"2025-12-19",{"date":62,"type":36},"2013-02",{"date":64,"type":21},"2038-01",{"name":66,"class":67},"Cancer Trials Ireland","NETWORK",6]